Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520936 · ClinicalTrials.gov registry record · Phase 2
A Study of Pemetrexed in Children With Recurrent Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00520936 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT00520936, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.
Interventions
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520936
The ClinicalTrials.gov registry entry for NCT00520936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pemetrexed is the first listed.
NCT00520936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00520936 about?
NCT00520936 is a clinical study titled "A Study of Pemetrexed in Children With Recurrent Cancer". To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET or non-brain s...
What is the current status of trial NCT00520936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2007-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00520936?
The interventions under investigation include: pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00520936?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.